Andrew Armstrong, MD
Medical Oncology · Durham, NCNPI 1528160199
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $247,417 of the $377,152 with a category attached, or 65.6%. It is spread thinly across 28 manufacturers, the largest accounting for just 22.0%. 2025 is the largest year on record at $99,555, 2.1 times the $47,178 reported in 2019. Among medical oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $1661.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$83K
- Astrazeneca UK Limited$49K
- Merck$46K
- Bayer$40K
- Astellas Pharma Europe Ltd$34K
- AstraZeneca$29K
- plus $96K from 22 others
Across 520 payments — averaging $16,055 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4.7M
- Bristol Myers Squibb$1M
- E.r. Squibb & Sons, L.L.C.$734K
- Astellas Pharma Global Development$417K
- Janssen Research & Development, LLC$365K
- Amgen$333K
- plus $777K from 7 others
What the payments were for
- Consulting fees$247,41766%
- Speaking & faculty fees$96,25226%
- Travel & lodging$27,8337%
- Food & beverage$5,4521%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 36 | $82,807 |
| Astrazeneca UK Limited | 21 | $49,284 |
| Merck | 24 | $45,896 |
| Bayer | 30 | $39,985 |
| Astellas Pharma Europe Ltd | 13 | $33,984 |
| AstraZeneca | 16 | $28,888 |
| E.r. Squibb & Sons, L.L.C. | 26 | $28,229 |
| Astellas Pharma Global Development | 10 | $18,124 |
| Astellas Pharma US Inc | 4 | $11,810 |
| Novartis | 6 | $6,130 |
| Amgen | 1 | $4,116 |
| Eisai Inc. | 3 | $3,530 |
| Janssen Global Services, LLC | 4 | $3,488 |
| Advanced Accelerator Applications | 1 | $3,144 |
| Exelixis Inc. | 3 | $2,837 |
| Dendreon Pharmaceuticals LLC | 5 | $2,375 |
| Sumitomo Pharma America, Inc. | 3 | $2,342 |
| Clovis Oncology, Inc. | 1 | $2,265 |
| Cipla USA Inc. | 1 | $2,000 |
| Bristol Myers Squibb | 2 | $1,996 |
| Telix Pharmaceuticals | 1 | $1,500 |
| Menarini Silicon Biosystems, Inc. | 3 | $816 |
| Myovant Sciences Inc. | 1 | $750 |
| Sanofi | 5 | $438 |
| Biosense Webster, Inc. | 3 | $167 |
| Progenics Pharmaceuticals, Inc. | 1 | $154 |
| Roche Products Limited | 1 | $53 |
| Janssen Scientific Affairs, LLC | 2 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$377,152 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 114 | $1,471,809 |
| CabometyxCabozantinib S-Malate | 26 | $572,343 |
| XtandiEnzalutamide | 41 | $493,050 |
| WeliregBelzutifan | 14 | $296,337 |
| InlytaAxitinib | 15 | $268,441 |
| OrgovyxRelugolix | 18 | $54,849 |
| Abiraterone Acetate | 140 | $51,199 |
| Prednisone | 158 | $718 |
| Bicalutamide | 21 | $276 |
| Dexamethasone | 19 | $240 |
| Prochlorperazine Maleate | 14 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $39,985 | $1,471,809114 claims |
| Exelixis Inc.Cabometyx | $2,837 | $572,34326 claims |
| Astellas Pharma US IncXtandi | $11,810 | $493,05041 claims |
| MerckWelireg | $45,896 | $296,33714 claims |
| PfizerInlyta | $82,807 | $268,44115 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $2,342 | $54,84918 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $45 | $51,199140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 medical oncology providers in North Carolina.
Other medical oncology in Durham
- Thomas LeblancDurham$1.7M
- John StricklerDurham$319K
- Neal ReadyDurham$309K
- Michael HarrisonDurham$161K
- Jeffrey ClarkeDurham$140K
- Sundhar RamalingamDurham$93K
- Arif KamalDurham$50K
- Nelson ChaoDurham$45K
- Laura AlderDurham$34K
- Kaushik SenDurham$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.